As bstract. Administration of human pancreatic tumor growth hormone (GH) releasing factor ) as a single injection to normal human subjects stimulates the secretion of GH in a dose-responsive manner. In the present studies, hpGRF(1-40) was infused in a graded stepwise manner over a 6-h period in order to determine whether the GH secretory response would be sustained. Normal adult males received four consecutive 90-min infusions of hpGRF(1-40) at doses of 1, 3.3, 10, and 33 ng/kg per min, preceded and followed by a 90-min saline infusion; and the plasma GH responses were compared with those during a separate control infusion.
Introduction
Growth hormone (GH)' secretion occurs in an episodic manner in response to a hypothalamic control mechanism, which involves a releasing and inhibiting factor. The regulation of GH secretion is complex and the interaction of the hypothalamic factors remains to be clarified. Structural characterization of a GH-releasing factor (GRF) that was isolated from ectopic production sites in two pancreatic tumors removed from patients with acromegaly has been recently reported (1, 2) . A 40-amino acid peptide, human pancreatic GRF (hpGRF) , was the only GRF identified in one tumor (1) and the major component in the other tumor (2) , which also contained hpGRF( 1-44) and hpGRF( 1-37). Although the structure of human hypothalamic GRF is not yet known, it appears to possess similar physicochemical and immunologic characteristics (3, 4) ; and two peptides that coelute with hpGRF( 1-40) and hpGRF( 1-44) have now been isolated and found to exhibit identical tryptic digest patterns and amino acid composition (5) .
Intravenous pulses of hpGRF( 1-40) (1 ,sg/kg) have been reported to stimulate GH secretion in normal men (6) and the responses are dose related, primarily during the second and third hour after injection (7) . After the injection of higher doses of GRF, evidence of a biphasic GH response was observed, which raised the possibility ofintermittent secretion or response attenuation. The present study was designed to explore this possibility by examining the GH secretory response to continuous stimulation by GRF by using a stepwise graded infusion. Since attenuation of the GH response could be mediated by increased hypothalamic somatostatin secretion (8, 9) , we also examined basal and thyrotropin-releasing hormone (TRH)-stimulated thyroid stimulating hormone (TSH) secretion during GRF infusion to indirectly assess possible influences of somatostatin.
Methods

Subjects studied
Experiments were performed in 15 healthy adult males whose ages ranged from 22 to 30 yr and who were within 15% of ideal body weight. All subjects gave informed, written consent. Experiments were conducted under identical protocols at the General Clinical Research Centers at the University of Cincinnati and University of Virginia Hospitals to which subjects were admitted the evening before or the morning of study. The subjects consumed no food for 10 h before or during the study. Separate indwelling "butterfly" needles were placed in forearm veins and kept patent with heparinized saline for infusion/injection and blood sampling. Blood pressure and pulse were monitored throughout the study at frequent intervals. Subjects were studied in random order in each of the protocols.
Hormone preparation
All experiments were performed with hpGRF(1-40), which was synthesized (1) and prepared (6) as previously described. Synthetic hpGRF(l-40) was diluted to a concentration of 100 gg/ml with human serum albumin (1 mg/ml) and then further diluted in normal saline to provide an appropriate concentration for constant infusion rates as described below. All dilutions were made in plastic syringes. Blood pressure and pulse were monitored throughout the infusion.
Infusion protocols
Graded GRF infusion. Eight subjects were infused for a 9-hour period beginning between 0800 and 0900 h. The study was divided into six 90-min segments. All subjects were infused with saline for the first 90 min. This was followed by sequential GRF infusions of 1, 3.3, 10, and 33 ng/kg per min, each of90 min length. During the last 90 min, subjects were again infused with saline. The volume of infusate during the 9-h study ranged from 200 to 250 ml. On a separate day each subject was infused with saline for a 9-h period, thereby serving as his own control.
GRF infusion-TRH injection. Seven subjects participated in a threeinfusion protocol, each of 5 h duration. In all protocols saline was infused during the 0-90-min and 210-300-min period. The three protocols for the 90-2 10-min period were as follows: In the first two protocols TRH was given 60 min after starting either saline infusion or GRF infusion (2 ng/kg per min). In the third protocol, saline was given as a bolus injection 60 min after starting a GRF infusion (2 ng/kg per min).
The total volume of infusate during the 5-h study ranged from 100 to 130 ml. GH and TSH radioimmunoassay (RIA) Plasma GH was measured by RIA as previously described (10) . The assay sensitivity was 0.1 ng/ml and the intra-and inter-assay coefficients of variation were 6.5 and 7.8%, respectively. Plasma TSH was measured by RIA as previously described (1 1), which was modified by delayed addition of tracer and further dilution of anti-TSH serum to provide an assay sensitivity of0.15 MU/ml. The intra-and inter-assay coefficients of variation were 7.1 and 8.1%, respectively. In both radioimmunoassays, polyethylene glycol (PE 6000) was added 5-10 min after the second antibody to produce immediate precipitation.
GRF bioassay
To test for possible adsorption to the plastic infusion syringes or degradation during infusion, the residual infusates from two of the graded GRF infusion protocols were appropriately diluted and bioassayed in primary monolayer cultures ofrat pituitary cells (12, 13) . Rat GH release into the incubation media was measured by RIA (14) .
GRE RIA
Plasma immunoreactive (IR)-GRF was measured by a double-antibody RIA using '25l-hpGRF(1-40) as tracer, rabbit anti-hpGRF (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , and hpGRF(1-40) as standard. The sensitivity of the assay was 15 pg/tube and the intra-and inter-assay coefficients ofvariation were 6.5 and 7.8%, at 1 ng/ml, respectively. IR-GRF was extracted from plasma by passage through a Sep-Pak (C-18 Cartridge, Waters Associates, Milford, MA), which was previously equilibrated with 0.01 M trifluoroacetic acid (TFA) and eluted with 80% acetonitrile in TFA. The details of the GRF RIA have been recently published (15) . IR-GRF was undetectable in plasma samples obtained before infusion of hpGRF(1-40).
Statistical analysis
Comparison of the GH and TSH secretory responses was made by an analysis of variance with repeated measures and by paired t test, as appropriate. Results were log-transformed before statistical analysis, when indicated, to improve comparability of variance. The in vitro GRF bioactive potency of the infusate was determined by a three-dose comparison with synthetic hpGRF(I-40) standard by means of covariance analysis.
Results
Plasma GH responses to graded GRF infusion. Plasma GH responses to GRF and to saline infusions among individual subjects exhibited considerable variability. Although all plasma GH levels were <5 ng/ml during the initial 90-min saline infusion in the 16 studies, all eight subjects demonstrated spontaneous pulses of GH secretion to levels of 5-36 ng/ml during the remainder of the control infusions. These pulses tended to occur during the latter portion of the study and were invariably noted during the last 90-min period. Secretory pulses of GH also occurred during the GRF infusion study, generally at times similar to those during the saline control infusions.
The results in four of the eight subjects are shown in Fig. response to the two lower doses of hpGRF( 1-40) but not to the 1 and are representative of the GH secretory patterns observed.
other doses. A postinfusion secretory pulse was also seen. HowSubject A exhibited a rise in GH levels in response to the lower ever, the secretory pattern during the saline control infusion three doses of GRF but not to the highest dose. A secretory was qualitatively and quantitatively similar. The GH responses pulse of GH also occurred after the end of the hpGRF in subject C were similar to those ofsubject A, though a decrease infusion. During the saline infusion, spontaneous GH secretion in GH levels occurred toward the end of each of the infusion occurred at 2 and 8 h. In subject B, GH secretion increased in doses, during which a GH response occurred. GH secretion in GH levels during the 1-, 3.3-, and 10-ng/kg per min doses and a gradual decline during the 33-ng/kg per min infusion to levels that were still, however, elevated when compared with those during the control infusion. In all but the 10-ng/kg per min infusion, a decrease in GH levels from peak values occurred at the end of each 90-min infusion. Although the individual GH secretory pulses were no longer discernible, an overall secretory pulse was still evident at 8 h during the control but not the hpGRF(1-40) study.
A quantitative estimation of the GH secretory response to increasing infusion rates of GRF is shown in Fig. 3 the period of study, underscoring the need for control studies in individual subjects.
Measurement of infusate GRF bioactivity and plasma IR-GRF levels. The bioactivity of hpGRF(1-40) in the infusate from two subjects, assayed in the rat pituitary cell culture system, is indicated in Table I . Each of the infusates was tested at three separate doses; and the results were compared with synthetic standard. The potency of each of the infusates was indistinguishable from that of the standard, which indicated no loss of bioactivity during the infusion.
Plasma IR-GRF levels (mean±SE) at the end ofeach infusion period are shown in Table II . The levels in circulation increased in proportion to the infusion rate throughout the entire dose range used.
Plasma TSH responses to graded GRF infusion. Plasma TSH levels during the hpGRF(1-40) infusion were indistinguishable from those during the saline control infusion, as shown in Fig. 4 . In both studies there was a tendency for plasma TSH levels to decrease during the period of observation. The effect of a GRF infusion on the plasma TSH response to TRH is shown in Fig. 5 . The infusion of GRF for 1 h before and 1 h after the injection of TRH had no inhibitory effect on the peak TSH response to TRH nor the magnitude of the TSH secretory response. The plasma GH level (mean±SE) at the time of TRH injection in the hpGRF(1-40) infusion group was 10.0±2.6 ng/ ml as compared with 1.0±0.3 ng/ml in the saline infusion group.
Clinical responses to GRF. Blood pressure and pulse were monitored throughout the infusions and no significant changes were detected. Three subjects complained of mild headaches at various times beginning 5 h after the start of the graded dose hpGRF(l -40) infusion. One subject also noted a headache during the control study. One subject became nauseated and vomited near the end of the highest dose hpGRF(1-40) infusion and again during the subsequent saline infusion. The characteristic clinical effects of TRH (warmth, micturation urge, metallic taste, and nausea) were unaltered when TRH was given during the hpGRF(1-40) infusion.
Discussion
The present results clearly indicate that constant infusions of hpGRF(1-40) stimulate GH secretion in normal male subjects and that the response is dose dependent. The maximal GH response was observed at an infusion rate of 10 ng/kg per min, the half-maximal effective dose (ED50) was calculated to be 1.9 ng/kg per min and the minimal stimulatory dose was 1 ng/kg per min. Although lower doses were not tested, it is unlikely could be attributed to spontaneous GH secretory pulses, which raise the possibility of time entrainment of GH secretion within individual subjects. Moreover, integrated GH secretion during the saline-control study did not remain constant, but increased with time to a value six times that during the initial 90-min basal period, at which time no spontaneous pulses were observed. Thus, it was essential to use the saline-control infusion in each subject when analyzing the results.
Inspection of the mean GH responses and even more strikingly, the individual responses, offered unequivocal evidence of intermittant secretion or of attenuation of the GH response. This was seen in individual subjects irrespective of dose and in the entire group, most prominently at the highest dose studied. Although the design of the present study did not permit a differentiation between the effects of time and dose, several possible explanations for the findings merit consideration. First, it could be argued that pituitary GH content was significantly depleted by the time of the highest dose hpGRF(l-40) infusion. Constant infusions of hpGRF(1-40) in rats result in a similar qualitative GH secretory pattern, which has been attributed to depletion of pituitary GH stores (16). The quantity of GH secreted in response to the lower three doses can be determined by multiplying the integrated secretion area, shown in Fig. 3 , (ng. min ml-') by the GH metabolic clearance rate (190 ml X min-') (17) . GH secretion, calculated in this manner (-370 ,g ), represents only a small fraction ofthe total pituitary GH content (10-15 mg) (18) and therefore cannot be considered to represent significant depletion.
Second, the possibility exists that a selective intracellular pool of GH within the somatotroph, susceptible to GRF-stimulated release rather than total somatotroph GH, was depleted. Multiple pools of GH have been shown to exist in the somatotroph (19) , which can be differentially stimulated by various secretagogues (20) . An argument against this hypothesis, however, is derived from the observation that GRF is capable of stimulating the release of nearly 50% of the GH contained in rat pituitary monolayer cultures during a 4-h incubation period (21) . Unless marked differences exist between rat and human somatotrophs and between in vitro and in vivo models, selective pool depletion is unlikely as an explanation for the attenuation.
A third possibility considered for the lack of response to the top infusion dose was that of degradation of hpGRF( 1-40) during infusion or enhanced metabolic clearance, which resulted in reduced bioactive GRF levels in circulation. This was excluded by the demonstration that (a) GRF bioactivity of the infusate was completely preserved at the end of the infusion, and (b) plasma IR-GRF levels rose in proportion to the infusate concentration.
A fourth and physiologically more plausible explanation is that the elevated plasma GH levels stimulated hypothalamic somatostatin release which, in turn, inhibited the GH response to GRF. Refractoriness of GH secretion to repeated stimulation by L-dopa (22) or sequential exercise and arginine infusion (23) has been previously demonstrated. Furthermore, exogenous GH administration inhibits spontaneous pulsatile endogenous GH secretion in the rat (24) and inhibits nyctohemeral (25) and insulin- (26) , arginine-, or exercise-induced (23) GH secretion in man by unknown but possibly somatostatin-mediated mechanisms. GH stimulates somatostatin release from the rat hypothalamus in vitro within 20 min at a concentration of 20 ng/ ml (8) . We made no attempt to measure plasma somatostatin levels, however, since peripheral circulating somatostatin is believed to originate from sites other than the hypothalamus.
Evidence for a somatostatin-mediated inhibition of the GH response to GRF was initially sought by measuring plasma TSH levels during the graded GRF infusion on the assumption that an increase in hypothalamic somatostatin release might suppress basal TSH secretion. Although the TSH assay exhibited sufficient sensitivity to detect reductions of up to 75% in basal TSH levels and is capable of distinguishing between basal TSH levels in normal and thyrotoxic subjects, no differences were observed between hpGRF( 1-40) and saline-control studies. Since, in the initial studies, intermittent secretion was observed at doses as low as 1 ng/kg per min, we infused hpGRF(1-40) at a rate of 2 ng/kg per min, which should have been sufficient to stimulate endogenous hypothalamic somatostatin release. TRH-stimulated TSH secretion was chosen as a possibly more sensitive system to demonstrate inhibition by somatostatin. Once again, there was no inhibition of the TSH response and thus no evidence to implicate increased somatostatin secretion as the mechanism responsible for the attenuation of the GH response. It must be acknowledged that the sensitivity of the somatotroph as compared with the thyrotroph to inhibition by somatostatin has not yet been systematically determined and it is conceivable that somatotroph inhibition could occur at a hypothalamic-hypophyseal portal plasma concentration to which the thyrotroph is insensitive.
As a fifth alternative, it is possible that impaired GH responsiveness to continuous hpGRF(1-40) infusion involves a cellular mechanism at the level of the somatotroph. Whether this represents receptor down-regulation or a postreceptor phenomenon is unknown, though there is precedence to support the former alternative. Quantitative reduction of pituitary receptors to gonadotropin-releasing hormone (GnRH) (27) , corticotropin releasing factor (28), dopamine (29) , and somatostatin (30) have been demonstrated after exogenous administration or physiologic perturbations, which result in enhanced endogenous secretion. It is therefore not unreasonable that a similar mechanism exists with respect to the GRF receptor. The data presented make a strong argument in favor of a homeostatic regulatory phenomenon. However, the syndrome of acromegaly associated with ectopic GRF secretion suggests that the phenomenon is modulatory rather than absolute, in contrast to studies with GnRH where gonadotropin secretion can be abolished by continuous GnRH administration.
Finally, consideration must be given to the occurrence of spontaneous GH secretory pulses during the period of hpGRF( 1-40) infusion, above and beyond the difficulty encountered in distinguishing them from responses to exogenous GRF. This is most clearly seen in Fig. 1 (32) . The implications of these findings as related to the feedback regulation of hypothalamic GRF secretion remain to be explored.
